GI-6207

also known as Recombinant Saccharomyces cerevisiae-CEA (610D) · Yeast CEA Vaccine

Developed for: colorectal cancer · malignant pancreatic neoplasm · triple-negative breast carcinoma · breast cancer · head and neck cancer · head and neck squamous cell carcinoma · hepatocellular carcinoma · lung cancer
+5 more
· medullary thyroid gland carcinoma · non-small cell lung carcinoma · prostate cancer · squamous cell carcinoma · urothelial carcinoma
Investigated by: ImmunityBio, Inc. · National Cancer Institute (NCI) · NantCell, Inc.

Trials 13

today NCT03563157 · Ph 1/2 NCT03554109 · Ph 2 NCT03169777 · Ph 1/2 NCT03563144 · Ph 2 NCT03586869 · Ph 1/2 NCT03563170 · Ph 1/2 NCT03169738 · Ph 1/2 NCT03387111 · Ph 1/2 NCT03169764 · Ph 1/2 NCT03175666 · Ph 1/2 NCT03197571 · Ph 1/2 NCT01856920 · Ph 2 NCT00924092 · Ph 1

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT00924092	Mar 2009 → Aug 2012	breast cancer, colorectal cancer, head and neck cancer, lung cancer +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/29 trials
Phase 1/2	NCT03563157	Sep 2018 → Apr 2019	colorectal cancer	ImmunityBio, Inc.	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT03169777	Aug 2018 → Jan 2019	colorectal cancer	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 1/2	NCT03586869	Jul 2018 → Apr 2019	malignant pancreatic neoplasm	ImmunityBio, Inc.	Terminated	No outcome recorded
Phase 1/2	NCT03563170	May 2018 → Aug 2019	hepatocellular carcinoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1/2	NCT03169738	Feb 2018 → Jan 2019	non-small cell lung carcinoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 1/2	NCT03387111	Jan 2018 → Apr 2019	squamous cell carcinoma	ImmunityBio, Inc.	Terminated	No outcome recorded
Phase 1/2	NCT03169764	Dec 2017 → Jan 2019	head and neck squamous cell carcinoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 1/2	NCT03175666	Dec 2017 → Jan 2019	triple-negative breast carcinoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 1/2	NCT03197571	Dec 2017 → Jan 2019	urothelial carcinoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 23 trials · 1 missed
Phase 2	NCT03554109	Sep 2018 → Jun 2020	triple-negative breast carcinoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT03563144	Aug 2018 → Dec 2019	malignant pancreatic neoplasm	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT01856920	Mar 2013 → May 2018	medullary thyroid gland carcinoma	NantCell, Inc.	Completed	Missed primary
Comparator or background therapy2 trials
Phase 1/2	NCT03387085 Background	Mar 2018 → Sep 2020	triple-negative breast carcinoma	ImmunityBio, Inc.	Terminated	No outcome recorded
Phase 1/2	NCT03167177 Background	Dec 2017 → Jan 2019	melanoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded

Press releases naming this drug 2 releases

Date	Issuer	Release
2015-08-04	GlobeImmune	UPDATE – Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy globeimmune.com ↗
2015-08-04	GlobeImmune	Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy globeimmune.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

Field	Value	Cited text
Known as	GI-6207	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03197571 ↗ 14 NCT03563157 ↗ NCT03387085 ↗ NCT03167177 ↗ NCT01856920 ↗ NCT03554109 ↗ NCT03169764 ↗ NCT03169777 ↗ NCT03175666 ↗ NCT03169738 ↗ NCT03563144 ↗ Show 4 more sources
Known as	Recombinant Saccharomyces cerevisiae-CEA (610D)	“GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]” NCT01856920 ↗
Known as	Yeast CEA Vaccine	“(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])” NCT00924092 ↗
Action	Deplete	“Researchers want to see if GI-6207 can encourage the body's immune system to attack and kill tumor cells that contain the CEA protein.” NCT01856920 ↗
Modality	Vaccine	“Vaccine (GI-6207)” NCT00924092 ↗
Route	Subcutaneous	“GI 6207 vaccine will be administered subcutaneously” NCT00924092 ↗